| Fund ID | 805-6556194744 |
| Fund type | Hedge Fund |
| 3(c)(1) exclusion | No |
| 3(c)(7) exclusion | Yes |
| Master fund | Yes |
| Feeder fund | No |
| Fund of funds | No |
| Relies on exemption from registration | Yes |
| Annual audit | Yes |
| Prepared per GAAP | Yes |
| Sub-advised | No |
| % of assets independently valued | 100% |
| Owned by the adviser or related persons | 33% |
| Owned by funds of funds | 22% |
| Owned by non-U.S. persons | 15% |
| Fund | Type | Gross assets |
|---|---|---|
| Sofinnova Bioequities Enhanced Master Fund, LP | Hedge | $834.3M |
| Sofinnova Venture Partners IX, L.P. | Venture Capital | $320.2M |
| Sofinnova Venture Partners X, L.P. | Venture Capital | $293.9M |
Sofinnova Bioequities Master Fund, Ltd. reports $172 million in gross assets, among the top 33% of private funds by size.
The stated minimum investment is $3 million.
Sofinnova Bioequities Master Fund, Ltd. is managed by Sofinnova Investments, Inc.
No. Private funds are not required to publicly disclose performance. Form ADV reports assets, structure, and service providers.